Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia.
Daver, Naval, Altman, Jessica K. , Begna, Kebede H. , Lunghi, Monia, Burke, Patrick W. , Schliemann, Christoph , Oshrine, Benjamin , Sallman, David A. , Daver, Naval , Montesinos, Pau , Advani, Anjali S. , Wang, Eunice S. , Garciaz, Sylvain , Martinelli, Giovanni , Roboz, Gail J. , Walter, Roland B. , Platzbecker, Uwe , Vyas, Paresh , Curti, Antonio , DeAngelo, Daniel J. , Gastaud, Lauris

Mayo Clinic

Journal of Clinical Oncology | June 10, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS6585-TPS6585

10.1200/jco.2024.42.16_suppl.tps6585 Get It

TPS6585 Background: Despite improved outcomes with azacitidine (AZA) and venetoclax (VEN) in newly diagnosed (ND) unfit acute myeloid leukemia (AML), only a subset of patients (pts) respond (CR 37%; CR/CRi 66%) and long-term survival remains inadequate (mOS <15m, DiNardo NEJM 2020). The measurable residual disease (MRD)-negative rate was 41% in AZA-VEN treated pts in VIALE-A which was associated with improved survival (Pratz JCO 2022). CD123 is expressed on the majority of AML blasts and leukemic stem cells while minimally expressed on normal hematopoietic stem cells (Kovtun Blood Adv 2018). Pivekimab sunirine (PVEK, IMGN632) is an antibody-drug conjugate comprising a high-affinity CD123 antibody, cleavable linker, and an indolinobenzodiazepine pseudodimer (IGN) payload. The IGN payload alkylates DNA and causes single strand breaks without crosslinking. IGNs are designed to have high potency against tumor cells, while demonstrating less toxicity to normal marrow progenitors than other DNA-targeting payloads. Clinical data from the first 50 pts in the dose expansion cohorts 1 and 2 with ND AML demonstrated a 76% (22/29) MRD negativity rate (by flow cytometry, negativity threshold <0.1%) (Daver ASH 2023), supporting the continued enrollment of the PVEK+AZA+VEN triplet and further evaluation of the regimen’s antileukemia activity and safety in consideration of potential registration-enabling trials. Methods: This is an open-label, multicenter, phase 1b/2 study of PVEK administered in a combination with AZA+VEN in pts with ND CD123-positive (CD123+ by flow cytometry or IHC) AML, with no prior treatment with hypomethylating agents (HMA). Pts will receive the recommended phase 2 dose of PVEK 0.045 mg/kg IV as a < 30-minute outpatient infusion on day 7, AZA 75 mg/m2 SC or IV daily on days 1 to 7, and VEN 400 mg PO daily for up to 28 days in a 28-day cycle. During cycle 1, a bone marrow evaluation at or around day 21 is required to inform VEN dose duration. Current eligibility criteria for continued enrollment of AML patients unfit for intensive chemotherapy include age ≥ 75 years old, or age < 75 years old with ECOG 2-3, or at least one defined comorbidity. The primary study objectives are to assess antileukemia clinical activity (composite CR [complete remission] rate, overall response rate, duration of remission) and MRD-negativity rates. Key secondary objectives are safety and tolerability, pharmacokinetics and immunogenicity. The PVEK+AZA+VEN triplet in pts with ND unfit AML is currently enrolling across sites in France, Germany, Italy, Spain, UK and USA. Clinical trial information: NCT04086264 .
Predictors of hypercontractile heart phenotype in patients with chronic coronary syndromes or heart failure
Cortigiani, Lauro , Souto, Germán, Djordjevic‐Dikic, Ana , Reisenhofer, Barbara, Boshchenko, A , Rigo, F , Merli, Elisa , Lisi, Matteo , Simova, Iana , Pitino, Annalisa , Nes, Michele De, Tripepi, Giovanni Luigi, Yin, Lixue , Picano, Eugenio , Boshchenko, Alla , Wang, Yi , Ciampi, Quirino , Zagatina, A , Kasprzak, Jarosław D. , Wierzbowska‐Drabik, Karina , Haberka, Maciej , Lowenstein, Jorge , Arbucci, Rosina , Haber, Diego M. Lowenstein, Marconi, Sofia, Merlo, Pablo , Barral, Patricia, Ryabova, Tamara , Rodríguez‐Zanella, Hugo , D’Andrea, Antonello , Gaibazzi, Nicola , Barbieri, Andréa , Morrone, Doralisa , Citro, Rodolfo , Carerj, Scipione , Pepi, Mauro , Pellikka, Patricia A. , group, on behalf of the Stress Echo 2030 study

Mayo Clinic

No container title available | June 10, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4476811/v1 Get It

Abstract Background Hypercontractile phenotype (HP) of the left ventricle (LV) is an actionable therapeutic target in patients with chronic coronary syndromes (CCS) or heart failure (HF), but its clinical recognition remains difficult. Objectives To assess the clinical variables associated with the HP. Methods In a prospective, observational, multicenter study, we recruited 5,122 patients (age 65 ± 11 years, 2974 males, 58%) with CCS and/or HF with preserved ejection fraction (EF). Systolic blood pressure (SBP) was measured. We assessed wall motion score index (WMSI), LV end-diastolic volume (EDV), end-systolic volume (ESV), EF, force (SBP/ESV), stroke volume (SV), arterial elastance (SBP/SV), and ventricular-arterial coupling (VAC, as SV/ESV). Univariable and multivariable logistic regression analysis assessed independent factors associated with the highest force sextile. Results For all the studied patients, force was 4.51 ± 2.11 mmHg/ml, with the highest sextile (Group 6) > 6.36 mmHg/ml. By multivariable logistic regression model, the highest sextile of force was associated with age > 65 years (OR 1.62, 95% CI 1.36–1.93, p < 0.001), hypertension (OR 1.76, 95% CI 1.40–2.21, p < 0.001), female sex (OR 4.52, 95% CI 3.77–5.42, p < 0.001), absence of beta-blocker therapy (OR 1.41, 95% CI 1.16–1.68), rest SBP ≥ 160 mmHg (OR 2.81, 95% CI 2.21–3.56, p < 0.001), high heart rate (OR 2.08, 95% CI 1.61–2.67, p < 0.001), and absence of prior myocardial infarction (OR 1.34, 95% CI 1.07–1.68, p = 0.012). Patients in the highest sextile of force showed lower values of WMSI, SV, EDV, and ESV, and higher values of arterial elastance and VAC. Conclusions HP of the LV with high force was clinically associated with advanced age, female sex, high resting SBP, and the absence of 𝛽-blocker therapy. By transthoracic echocardiography, HP was associated with a small heart with reduced EDV, reduced SV despite high EF, and higher arterial elastance.
Efficacy of pembrolizumab monotherapy and in combination with BCR inhibitors for Richter transformation of chronic lymphocytic leukemia (CLL).
LaPlant, Betsy, Leis, José F., Call, Timothy G., He, Rong , Micallef, Ivana N. , Nowakowski, Grzegorz S. , Koehler, Amber B. , Hampel, Paul J. , Aitken, Casey N., Ansell, Stephen M. , Wang, Yucai , Parikh, Sameer A. , Shanafelt, Tait D. , Habermann, Thomas M. , Witzig, Thomas E. , Kenderian, Saad S. , Muchtar, Eli , Sinha, Sutapa , Kay, Neil E. , Ding, Wei

Mayo Clinic

Journal of Clinical Oncology | June 10, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 7050-7050

10.1200/jco.2024.42.16_suppl.7050 Get It

7050 Background: The management of Richter transformation (RT) of CLL represents an unmet clinical need. We previously reported modest efficacy of pembrolizumab monotherapy in an initial cohort of patients with RT (Ding, et al, Blood 2017). Here we report updated results of this trial, including an expansion cohort and a combination therapy cohort. Methods: Patients with biopsy proven RT to diffuse large B-cell lymphoma were enrolled and treated with single agent pembrolizumab (200 mg IV Q3W). Patients with progressive disease (PD) or stable disease (SD) after 3 months of pembrolizumab monotherapy were allowed to add a B-cell receptor (BCR) kinase inhibitor. The primary end point was overall response rate (ORR). Results: A total of 26 patients with RT were enrolled (9 in initial cohort and 17 in expansion cohort). The median age was 68.5 years. Ten (38%) patients had del(17p) or TP53 mutation. The median number of prior lines of therapy was 3 (range 1-10). Fifteen (58%) patients had received ibrutinib previously (14 of whom had PD on ibrutinib). With pembrolizumab monotherapy (n=26), the ORR was 23.1%, with 2 (7.7%) complete response (CR), 4 (15.4%) partial response (PR), and 7 (26.9%) SD. Of the 6 patients with confirmed CR or PR, responses occurred after a median of 2 cycles of monotherapy. The median duration of response (DOR) was 3.2 months (95% CI 2.8-NA). The median progression-free survival (PFS) was 2.6 months (95% CI 1.6-3.6). Sixteen patients went on to receive a BCR kinase inhibitor (ibrutinib [n=15], idelalisib [n=1]) in combination with pembrolizumab, after SD or PD on pembrolizumab monotherapy. The ORR to combination therapy was 62.5%, with 4 (25.0%) CR and 6 (37.5%) PR. Of the 10 patients with confirmed CR or PR to combination therapy, responses occurred after a median of 4 cycles of therapy. The median DOR was 4.5 months (95% CI 1.6-NA). The median PFS was 7.6 months (95% CI 2.3-13.3). After a median follow-up of 50.4 (95% CI 34.0-56.0) months, the median overall survival (OS) for all 26 patients with RT was 11.6 months (95% CI 7.5-20.1), and the 2-year OS rate was 27%. Treatment-related adverse events (TRAEs) of any grade occurred in 24 (92%) patients, including anemia (54%), thrombocytopenia (58%), neutropenia (54%), leukopenia (35%), lymphopenia (23%), dyspnea (23%), diarrhea (19%), and nausea (23%). Treatment-related grade 3 or above AEs occurred in 21 (81%) patients, including neutropenia (38%), leukopenia (31%), thrombocytopenia (27%), anemia (15%), febrile neutropenia (12%), and lung infection (12%). Conclusions: This expanded analysis confirmed that pembrolizumab has modest single agent activity in RT. Combination therapy with pembrolizumab and a BCR kinase inhibitor is associated with increased efficacy (ORR >60%), similar to other reports. These results support further investigation of immune checkpoint inhibitor-based combination therapy in RT. Clinical trial information: NCT02332980 .
Anticoagulation during extracorporeal membrane oxygenation
Seelhammer, Troy G. , Ninan, Jacob , Nei, Scott D. , Nabzdyk, Christoph GS, Gerberi, Dana , Wieruszewski, Patrick M. , Nei, Scott, Wieruszewski, Patrick M , Nabzdyk, Christoph S. , Wang, Zhen

Mayo Clinic

Cochrane Database of Systematic Reviews | June 10, 2024 | Volume: 2024 | Issue: 6 | Pages: No page available

10.1002/14651858.cd015685 | PMID 39804113 Get It

Biomechanical Properties and Kinematics of Medial Patellofemoral Ligament Reconstruction: A Systematic Review
Walsh, Justin M. , Credille, Kevin , Darbandi, Azad D., Huddleston, Hailey P. , Wang, Zachary , Dandu, Navya , Yanke, Adam B. , Allahabadi, Sachin , Kaplan, Daniel James , Hevesi, Mario

Mayo Clinic

Orthopaedic Journal of Sports Medicine | June 7, 2024 | Volume: 12 | Issue: 6 | Pages: No page available

10.1177/23259671241241537 | PMID 38855071 Get It

Background: While the biomechanical properties of the native medial patellofemoral ligament (MPFL) have been well studied, there is no comprehensive summary of the biomechanics of MPFL reconstruction (MPFLR). An accurate understanding of the kinematic properties and functional behavior of current techniques used in MPFLR is imperative to restoring native biomechanics and improving outcomes. Purpose: To provide a comprehensive review of the biomechanical effects of variations in MPFLR, specifically to determine the effect of graft choice and reconstruction technique. Study Design: Systematic review. Methods: A systematic review was performed in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. A total of 32 studies met inclusion criteria: (1) using ≥8 human cadaveric specimens, (2) reporting on a component of MPFLR, and (3) having multiple comparison groups. Results: Gracilis, semitendinosus, and quadriceps grafts demonstrated an ultimate load to failure (N) of 206.2, 102.8, and 190.0 to 205.0 and stiffness (N/mm) of 20.4, 8.5, and 21.4 to 33.6, respectively. Single-bundle and double-bundle techniques produced an ultimate load to failure (N) of 171 and 213 and stiffness (N/mm) of 13.9 and 17.1, respectively. Anchors placed centrally and superomedially in the patella produced the smallest degree of length changes throughout range of motion in contrast to anchors placed more proximally. Sutures, suture anchors, and transosseous tunnels all produced similar ultimate load to failure, stiffness, and elongation data. Femoral tunnel malpositioning resulted in significant increases in contact pressures, patellar translation, tilt, and graft tightening or loosening. Low tension grafts (2 N) most closely restored the patellofemoral contact pressures, translation, and tilt. Graft fixation angles variably and inconsistently altered contact pressures, and patellar translation and tilt. Conclusion: Data demonstrated that placement of the MPFLR femoral tunnel at the Schöttle point is critical to success. Femoral tunnel diameter should be ≥2 mm greater than graft diameter to limit graft advancement and overtensioning. Graft fixation, regardless of graft choice or fixation angle, is optimally performed under minimal tension with patellar fixation at the medial and superomedial patella. However, lower fixation angles may reduce graft strain, and higher fixation angles may exacerbate anisometry and length changes if femoral tunnel placement is nonanatomic.
A phase 2 randomized trial of neoadjuvant enoblituzumab versus standard of care in men with high-risk localized prostate cancer: The help elucidate and attack longitudinally (HEAT) prostate cancer randomized study.
Wang, Hao , Shah, Paras , Yang, Ximing J. , Murugan, Paari , Gupta, Sounak , Warlick, Christopher A. , Boorjian, Stephen A. , Ross, Ashley E. , Shenderov, Eugene , Marzo, Angelo M. De , Lotan, Tamara Levin , Schaeffer, Edward M. , Hussain, Maha , Sartor, Oliver , Pavlovich, Christian P. , Antonarakis, Emmanuel S. , Allaf, Mohamad E

Mayo Clinic

Journal of Clinical Oncology | June 6, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS5125-TPS5125

10.1200/jco.2024.42.16_suppl.tps5125 Get It

TPS5125 Background: B7-H3 is a member of the B7 superfamily, which includes PD-L1 (B7-H1) and PD-L2 (B7-DC). Enoblituzumab is a humanized Fc-optimized B7-H3–targeting antibody that induces antibody-dependent cellular cytotoxicity (ADCC). A recent investigator-initiated trial demonstrated that enoblituzumab therapy, used in the neoadjuvant prostate cancer setting, is feasible, safe, may enhance short-term clinical outcomes, and appears to stimulate intratumoral immune activation including CD8+ T cell infiltration and peripheral expansion of tumor-infiltrating T-cell clones that correlated with undetectable PSA at 1-year post-prostatectomy. To assess the impact of enoblituzumab on recurrence-free survival following prostatectomy, a phase 2, randomized, neoadjuvant clinical trial in high-risk localized prostate cancer patients has been started. We hypothesize that targeting B7-H3 with enoblituzumab will delay or prevent recurrence following prostatectomy compared to standard of care (SOC) . Methods: The HEAT trial is an investigator-initiated, multi-center, randomized, phase 2 study that is presently enrolling (NCT06014255). Eligible patients will undergo a pre-treatment prostate biopsy and conventional imaging (CT and bone scan) as well as PSMA-PET. Patients who have clinical stage cT1c-T3b, cN0 cM0 disease by conventional imaging (N1 by PSMA allowed with up to 3 LNs each ≤1 cm) will be eligible as long as concurrent hormonal or radiation therapy is not given. Prostate biopsy, within 3 months of enrollment, needs to show at least 3 positive cores containing at least 1 core with at least 50% disease involvement with Gleason ≥4+3=7 disease (with at least 1 additional high-risk feature such as PSA>20 ng/ml or cT3) or a Gleason sum ≥8. Patients will receive enoblituzumab at a dose of 15mg/kg IV biweekly for 6 doses (12 weeks) on the treatment arm, followed by prostatectomy, or will be scheduled for prostatectomy directly within 4-8 weeks on the SOC arm. 219 patients will be randomized (2:1) to treatment versus SOC. Pre-treatment, on-treatment, and post-treatment biomarkers of response and resistance will be collected. Patients will be followed according to standard institutional practices, but will require PSA evaluations every 3 (±1) months during year 1 and every 6 (±2) months during years 2-5. In both arms, salvage or adjuvant therapy will occur after biochemical or radiographic progression. The primary endpoint is recurrence-free survival (RFS) defined as any metastasis events, local pelvic visceral or lymph node recurrence, detectable prostate-specific antigen (PSA), or start of subsequent local or systemic therapy (including salvage or adjuvant therapy), or death for any cause, whichever occurs first. Secondary endpoints include additional clinical and immunologic correlates. Clinical trial information: NCT06014255 .
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers
Klomp, Jennifer E. , Stalnecker, Clint A. , Bryant, Kirsten L. , Edwards, A. Cole , Drizyte‐Miller, Kristina , Hibshman, Priya S. , Diehl, J. Nathaniel , Lee, Ye S. , Morales, Alexis Jean , Taylor, Khalilah E. , Peng, Sen, Tran, Nhan L. , Prevatte, Alex W., Hover, Laura D. , Hallin, Jill , Chowdhury, Saikat , Coker, Oluwadara , Olson, Peter , Christensen, James G. , Graves, Lee M. , Wennerberg, Krister , Klomp, Jeffrey A , Klomp, Jennifer E , Stalnecker, Clint A , Bryant, Kirsten L , Drizyte-Miller, Kristina , Diehl, J Nathaniel , Lee, Ye S , Morales, Alexis J , Taylor, Khalilah E , Herring, Laura E , Barker, Natalie K , Hallin, Jill , Chowdhury, Saikat , Coker, Oluwadara , Lee, Hey Min , Goodwin, Craig M , Gautam, Prson , Olson, Peter , Christensen, James G , Shen, John P , Kopetz, Scott , Graves, Lee M , Lim, Kian-Huat , Wang-Gillam, Andrea , Wennerberg, Krister , Cox, Adrienne D , Der, Channing J , Tran, Nhan L , Herring, Laura E. , Barker, Natalie K. , Gautam, Prson , Kopetz, Scott , Wang‐Gillam, Andrea , Cox, Adrienne D.

Mayo Clinic

Science | June 6, 2024 | Volume: 384 | Issue: 6700 | Pages: No page available

10.1126/science.adk0775 | PMID 38843331 Get It

How the KRAS oncogene drives cancer growth remains poorly understood. Therefore, we established a systemwide portrait of KRAS- and extracellular signal–regulated kinase (ERK)–dependent gene transcription in KRAS-mutant cancer to delineate the molecular mechanisms of growth and of inhibitor resistance. Unexpectedly, our KRAS-dependent gene signature diverges substantially from the frequently cited Hallmark KRAS signaling gene signature, is driven predominantly through the ERK mitogen-activated protein kinase (MAPK) cascade, and accurately reflects KRAS- and ERK-regulated gene transcription in KRAS-mutant cancer patients. Integration with our ERK-regulated phospho- and total proteome highlights ERK deregulation of the anaphase promoting complex/cyclosome (APC/C) and other components of the cell cycle machinery as key processes that drive pancreatic ductal adenocarcinoma (PDAC) growth. Our findings elucidate mechanistically the critical role of ERK in driving KRAS-mutant tumor growth and in resistance to KRAS-ERK MAPK targeted therapies.
Effect of intraocular pressure reduction on progressive high myopia (PHM study): study protocol of a randomised controlled trial
Jiang, Jingwen, Lin, Tingting , Lin, Fengbin , Kong, Kangjie, Song, Yunhe , Wang, Zhenyu , Jin, Ling, Liu, Yuhong , Gao, Xinbo , Chen, Jinmei, Chen, Meiling , Lam, Dennis S.C. , Chen, Shida , Zhou, Fengqi, Jonas, Jost B , Zhang, Xiulan , Wang, Peiyuan , Zhou, Fengqi , Zhang, Xiulan

Mayo Clinic

BMJ Open | June 5, 2024 | Volume: 14 | Issue: 6 | Pages: e084068

10.1136/bmjopen-2024-084068 | PMID 38839388 Get It

Background In adult patients with high myopia (HM), progressive axial elongation poses a significant risk for the development of subsequent ocular complications that may lead to visual impairment. Effective strategies to reduce or prevent further axial elongation in highly myopic adult patients have not been available so far. Recent studies suggested that medically lowering intraocular pressure (IOP) may reduce axial elongation. Objective This clinical randomised controlled trial (RCT) aims to evaluate the efficacy of medical IOP reduction in adult patients with progressive HM (PHM). Trial design Single-centre, open-label, prospective RCT. Methods This RCT will recruit 152 participants with PHM at the Zhongshan Ophthalmic Center (ZOC). Randomised in a ratio of 1:1, participants will receive IOP-lowering eyedrops (intervention group) or will be followed without treatment (control group) for 12 months. Follow-up visits will be conducted at 1, 6 and 12 months after baseline. Only one eye per eligible participant will be included for analysis. The primary outcome is the change in axial length (AL) within the study period of 12 months. Secondary outcomes include the incidence and progression of visual field (VF) defects, changes in optic disc morphology and incidence and progression of myopic maculopathy. Difference in AL changes between the two groups will be analysed using linear regression analysis. For the secondary outcomes, a multifactor Poisson regression within a generalised linear model will be used to estimate the relative risk of progression in VF defects and myopic maculopathy, and the rate of thinning in retinal nerve fibre layer and ganglion cell-inner plexiform will be assessed through Kaplan-Meier curves and log-rank tests. Ethics and dissemination Full ethics approval for this trial has been obtained from the Ethics Committee of ZOC, Sun Yat-sen University, China (ID: 2023KYPJ110). Results of this trial will be disseminated through peer-reviewed journals and conference presentations. Trial registration number NCT05850936 .
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Saner, Flurina A.M. , Takahashi, Kazuaki , Budden, Timothy , Pandey, Ahwan , Ariyaratne, Dinuka , Zwimpfer, Tibor A. , Meagher, Nicola S. , Twomey, Laura , Hoang, Therese, Group, for the Australian Ovarian Cancer Study, Christie, Elizabeth L. , Kang, Eun-Young , Nelson, Gregg , Riggan, Marjorie J. , Alsop, Jennifer , Beckmann, Matthias W. , Boros, Jessica , Brand, Alison H. , Carney, Michael E. , Coulson, Penny , Courtney‐Brooks, Madeleine , Cushing‐Haugen, Kara L. , El‐Bahrawy, Mona , Gayther, Simon A. , Hartmann, Arndt , Hendley, Joy , Jimenez-Linan, Mercedes , Jones, Michael E. , Kluz, Tomasz , Koziak, Jennifer M. , Kristjansdottir, Björg , Le, Nhu D. , Lener, Marcin , Lester, Jenny , Mateoiu, Constantina , Oršulić, Sandra , Ruebner, Matthias , Schoemaker, Minouk J. , Shah, Mitul , Sharma, Raghwa , Shvetsov, Yurii B. , Soong, T. Rinda , Sukumvanich, Paniti , Talhouk, Aline , Anglesio, Michael S. , Fasching, Peter A. , Goodman, Marc T. , Huntsman, David G. , Kelemen, Linda E. , Menon, Usha , Pharoah, Paul D.P. , Schildkraut, Joellen M. , Goode, Ellen L. , Ramus, Susan J. , Bowtell, David D.L. , Garsed, Dale W. , Fereday, Sian , Twomey, Laura , Pishas, Kathleen I , Hoang, Therese , Bolithon, Adelyn , Traficante, Nadia , Alsop, Kathryn , Christie, Elizabeth L , Kang, Eun-Young , Nelson, Gregg S , Ghatage, Prafull , Lee, Cheng-Han , Riggan, Marjorie J , Alsop, Jennifer , Beckmann, Matthias W. , Boros, Jessica , Brand, Alison H , Brooks-Wilson, Angela R , Carney, Michael E , Coulson, Penny , Courtney-Brooks, Madeleine , Cushing-Haugen, Kara L , Cybulski, Cezary , El-Bahrawy, Mona A , Elishaev, Esther , Erber, Ramona , Gayther, Simon A , Gentry‐Maharaj, Aleksandra , Gilks, C. Blake , Harnett, Paul R , Harris, Holly R , Hartmann, Arndt , Hein, Alexander , Hendley, Joy , Hernandez, Brenda Y , Jakubowska, Anna , Jimenez-Linan, Mercedes , Jones, Michael E , Kaufmann, Scott H , Kennedy, Catherine J , Kluz, Tomasz , Koziak, Jennifer M , Kristjansdottir, Björg , Le, Nhu D , Lener, Marcin , Lester, Jenny , Lubinski, Jan , Mateoiu, Constantina , Orsulic, Sandra , Ruebner, Matthias , Schoemaker, Minouk J , Shah, Mitul , Sharma, Raghwa , Sherman, Mark E , Shvetsov, Yurii B , Soong, T Rinda , Steed, Helen , Sukumvanich, Paniti , Talhouk, Aline , Taylor, Sarah E , Vierkant, Robert A , Wang, Chen , Widschwendter, Martin , Wilkens, Lynne R , Winham, Stacey J , Anglesio, Michael S , Berchuck, Andrew , Brenton, James D , Campbell, Ian G , Cook, Linda S. , Doherty, Jennifer A , Fasching, Peter A , Fortner, Renée T , Goodman, Marc T , Gronwald, Jacek , Huntsman, David G , Karlan, Beth Y , Kelemen, Linda E , Menon, Usha , Modugno, Francesmary , Pharoah, Paul D P , Schildkraut, Joellen M , Sundfeldt, Karin , Swerdlow, Anthony J , Goode, Ellen L , Fazio, Anna de , Köbel, Martin , Ramus, Susan J , Bowtell, David D , Garsed, Dale W , Ariyaratne, Dinuka , Pandey, Ahwan , Fereday, Sián , Traficante, Nadia , Group, for the Australian Ovarian Cancer Study, Alsop, Kathryn , Lee, Cheng‐Han , Brooks‐Wilson, Angela , Cybulski, Cezary , Elishaev, Esther , Harnett, Paul R. , Harris, Holly R. , Hein, Alexander , Hernandez, Brenda Y. , Jakubowska, Anna , Kaufmann, Scott H. , Kennedy, Catherine J. , Lubiński, Jan , Sherman, Mark E. , Steed, Helen , Vierkant, Robert A. , Wang, Chen , Widschwendter, Martin , Wilkens, Lynne R. , Winham, Stacey J. , Berchuck, Andrew , Brenton, James D. , Campbell, Ian , Doherty, Jennifer A. , Fortner, Renée T. , Gronwald, Jacek , Karlan, Beth Y. , Modugno, Francesmary , Swerdlow, Anthony J. , DeFazio, Anna , Köbel, Martin

Mayo Clinic

Clinical Cancer Research | June 5, 2024 | Volume: 30 | Issue: 16 | Pages: 3481-3498

10.1158/1078-0432.ccr-23-3552 | PMID 38837893 Get It

Abstract Purpose: The purpose of this study was to evaluate RB1 expression and survival across ovarian carcinoma histotypes and how co-occurrence of BRCA1 or BRCA2 (BRCA) alterations and RB1 loss influences survival in tubo-ovarian high-grade serous carcinoma (HGSC). Experimental Design: RB1 protein expression was classified by immunohistochemistry in ovarian carcinomas of 7,436 patients from the Ovarian Tumor Tissue Analysis consortium. We examined RB1 expression and germline BRCA status in a subset of 1,134 HGSC, and related genotype to overall survival (OS), tumor-infiltrating CD8+ lymphocytes, and transcriptomic subtypes. Using CRISPR-Cas9, we deleted RB1 in HGSC cells with and without BRCA1 alterations to model co-loss with treatment response. We performed whole-genome and transcriptome data analyses on 126 patients with primary HGSC to characterize tumors with concurrent BRCA deficiency and RB1 loss. Results: RB1 loss was associated with longer OS in HGSC but with poorer prognosis in endometrioid ovarian carcinoma. Patients with HGSC harboring both RB1 loss and pathogenic germline BRCA variants had superior OS compared with patients with either alteration alone, and their median OS was three times longer than those without pathogenic BRCA variants and retained RB1 expression (9.3 vs. 3.1 years). Enhanced sensitivity to cisplatin and paclitaxel was seen in BRCA1-altered cells with RB1 knockout. Combined RB1 loss and BRCA deficiency correlated with transcriptional markers of enhanced IFN response, cell-cycle deregulation, and reduced epithelial–mesenchymal transition. CD8+ lymphocytes were most prevalent in BRCA-deficient HGSC with co-loss of RB1. Conclusions: Co-occurrence of RB1 loss and BRCA deficiency was associated with exceptionally long survival in patients with HGSC, potentially due to better treatment response and immune stimulation.